6-MP 50mg (Mercaptopurine) Tablets

6-MP 50mg contains mercaptopurine 50mg, a prescription antimetabolite medicine used in combination chemotherapy for acute lymphoblastic leukemia (ALL). The medicine interferes with processes that leukemia cells need to grow and multiply. Treatment requires specialist supervision because mercaptopurine can affect blood counts, the liver, and the immune system.

What is 6-MP 50mg?

6-MP 50mg is an oral tablet containing mercaptopurine 50mg. The abbreviation 6-MP refers to 6-mercaptopurine.

Mercaptopurine belongs to the antimetabolite class of medicines. It interferes with purine-related processes that cells need to produce genetic material.

Because rapidly dividing leukemia cells depend heavily on these processes, mercaptopurine can help control abnormal cell growth during leukemia treatment.

What Is Mercaptopurine Used For?

Mercaptopurine is primarily used as part of combination chemotherapy for acute lymphoblastic leukemia (ALL).

Current U.S. labeling indicates mercaptopurine tablets for adult and pediatric patients with ALL as part of a combination chemotherapy maintenance regimen. :contentReference[oaicite:2]{index=2}

Mercaptopurine has also been used for other medical conditions in some clinical settings. However, those uses may differ from the current U.S. approved indication. Your specialist should determine whether mercaptopurine is appropriate for your condition.

What Is Mercaptopurine Used For in ALL?

Acute lymphoblastic leukemia is a cancer involving immature lymphoid blood cells. Treatment usually involves several phases and multiple medicines.

Mercaptopurine can form part of the maintenance chemotherapy phase. The exact treatment plan depends on the patient’s age, leukemia characteristics, previous treatment, laboratory results, and response to therapy.

Therefore, patients should use mercaptopurine only according to their oncology treatment plan.

How Does Mercaptopurine Work?

Mercaptopurine interferes with purine metabolism. Purines contribute to the production of DNA and RNA.

By disrupting these pathways, mercaptopurine reduces the ability of susceptible cells to produce the genetic material needed for growth and replication.

Leukemia cells can therefore become less able to multiply. This pharmacologic action contributes to mercaptopurine’s anticancer effect.

Mercaptopurine Mechanism of Action

Mercaptopurine mechanism of action involves intracellular conversion to active thiopurine metabolites.

These metabolites interfere with purine nucleotide synthesis and can also become incorporated into nucleic acids. The combined effects disrupt cellular replication and function.

For this reason, mercaptopurine is classified as a purine antagonist and antimetabolite.

6-MP 50mg Composition

• Active ingredient: Mercaptopurine
• Strength: 50mg per tablet
• Common name: 6-MP or 6-mercaptopurine
• Drug class: Antimetabolite
• Dosage form: Oral tablet

The pictured product is labeled as mercaptopurine tablets IP 50mg and 6-MP. Product information from Indian pharmaceutical sources identifies the 6-MP 50mg product with Zydus.

Mercaptopurine 50mg Dosage

The correct mercaptopurine 50mg dosage depends on the patient’s treatment protocol and clinical factors.

Current U.S. labeling lists a recommended starting dosage of 1.5mg/kg to 2.5mg/kg once daily as part of combination chemotherapy maintenance for ALL. Doctors adjust the dose according to blood counts and treatment response.

The 50mg tablet strength may not allow an appropriate dose for every patient, particularly smaller children. A specialist should calculate the dose rather than relying on the tablet strength alone.

Do not use this information as an individual dosing instruction. Follow the prescription and oncology protocol provided by your healthcare team.

How to Take 6-MP 50mg

• Take mercaptopurine exactly as prescribed.
• Take it at the same time each day when possible.
• Follow your oncology team’s instructions about food.
• Do not take extra tablets if you miss a dose.
• Do not stop treatment without speaking with your oncology team.

Consistent treatment helps maintain the intended chemotherapy schedule. Your healthcare team may change the dose when blood counts or other safety tests require an adjustment.

Mercaptopurine Side Effects

Mercaptopurine side effects can affect the digestive system, blood cells, liver, and immune system.

Possible side effects include:

• Nausea
• Vomiting
• Diarrhea
• Skin rash
• Hair loss
• Skin darkening
• Reduced blood-cell counts

Tell your healthcare professional if side effects become severe or continue. MedlinePlus also lists nausea, vomiting, skin darkening, hair loss, and rash among possible effects.

Serious Mercaptopurine Side Effects

Mercaptopurine can cause serious adverse reactions. Regular medical monitoring is essential during treatment.

Seek prompt medical attention for:

• Unusual bruising or bleeding
• Fever or chills
• Sore throat or other infection symptoms
• Severe weakness
• Shortness of breath
• Yellow skin or eyes
• Severe abdominal symptoms
• Swelling of the legs or ankles

These symptoms can indicate blood-cell suppression, infection, liver injury, or other serious complications.

Mercaptopurine and Low Blood Counts

Myelosuppression is an important risk with mercaptopurine.

The medicine can reduce white blood cells, red blood cells, and platelets. As a result, patients may develop infections, anemia, or increased bleeding.

Current U.S. labeling recommends regular complete blood count monitoring and dose adjustment when excessive myelosuppression occurs.

Mercaptopurine and Liver Problems

Mercaptopurine can cause hepatotoxicity. Liver function therefore requires appropriate monitoring during treatment.

Contact your healthcare team if you develop yellow skin or eyes, dark urine, unusual tiredness, abdominal swelling, or pain in the upper-right abdomen.

Current labeling includes hepatotoxicity as an important warning and precaution.

Mercaptopurine and TPMT

TPMT is an enzyme involved in the metabolism of thiopurine medicines.

Some people have inherited TPMT variations that reduce their ability to process mercaptopurine. These patients can face a greater risk of severe toxicity when standard doses are used.

Healthcare professionals may use TPMT information when selecting or adjusting treatment.

Mercaptopurine and NUDT15

NUDT15 is another genetic factor that can affect thiopurine tolerance.

Patients with reduced NUDT15 activity may have a higher risk of severe myelosuppression.

Current U.S. labeling includes dose modifications based on TPMT and NUDT15 deficiency.

Mercaptopurine and Allopurinol

Allopurinol can increase mercaptopurine exposure.

For this reason, the mercaptopurine dose may need a substantial reduction when the medicines are used together.

Never combine allopurinol and mercaptopurine without specific instructions from your healthcare professional. Current U.S. labeling specifically addresses dose modification with concomitant allopurinol.

Mercaptopurine and Mesalamine

Mesalamine and other aminosalicylates can interact with thiopurine medicines.

Tell your healthcare professional if you use mesalamine, sulfasalazine, or another aminosalicylate. Additional monitoring may be necessary.

Mercaptopurine and Warfarin

Mercaptopurine can affect the anticoagulant effect of warfarin.

Patients taking both medicines may require closer monitoring. Do not change your warfarin or mercaptopurine dose without medical advice.

Mercaptopurine and Methotrexate

Methotrexate and mercaptopurine can both form part of leukemia chemotherapy protocols. However, their use together requires specialist supervision.

The complete chemotherapy regimen determines the appropriate doses, timing, laboratory monitoring, and treatment adjustments.

Mercaptopurine and Cyclophosphamide

Cyclophosphamide is another chemotherapy medicine. It may appear in multi-drug cancer treatment protocols, but patients should never combine chemotherapy medicines independently.

Your oncology team selects each medicine according to the diagnosis, treatment phase, and individual response.

Mercaptopurine and Azathioprine

Azathioprine and mercaptopurine are closely related thiopurine medicines.

Because both medicines can produce significant toxicity, patients should not substitute one for the other without medical supervision.

Mercaptopurine for Crohn’s Disease

Mercaptopurine has also been used in some patients with Crohn’s disease. MedlinePlus lists Crohn’s disease and ulcerative colitis among other uses that may occur in clinical practice.

However, these uses differ from the current U.S. approved tablet indication, which is ALL maintenance chemotherapy. Discuss the risks and benefits with a qualified specialist before using mercaptopurine for an inflammatory bowel condition.

Mercaptopurine for Ulcerative Colitis

Mercaptopurine may be used in selected inflammatory bowel disease situations under specialist supervision.

Because the medicine suppresses immune activity and can cause serious adverse effects, routine blood and liver monitoring remains important.

Mercaptopurine and Infection Risk

Mercaptopurine can suppress the immune system and reduce protective blood cells.

As a result, infections can become more likely or more serious. Tell your healthcare professional promptly if you develop fever, chills, sore throat, or other signs of infection.

Do not receive vaccinations during treatment without first discussing them with your healthcare team. MedlinePlus specifically advises patients to consult their doctor before receiving vaccinations.

Mercaptopurine and Pregnancy

Mercaptopurine can harm a developing fetus. Tell your healthcare professional if you are pregnant, planning pregnancy, or could become pregnant.

Your oncology team should weigh the benefits and potential risks before treatment.

Current U.S. labeling includes embryo-fetal toxicity among the warnings and precautions.

Mercaptopurine and Breastfeeding

Discuss breastfeeding with your healthcare professional before taking mercaptopurine.

Current U.S. labeling advises against breastfeeding during mercaptopurine treatment.

Mercaptopurine Drug Interactions

Mercaptopurine has several clinically important drug interactions.

Important examples include:

• Allopurinol
• Warfarin
• Mesalamine
• Sulfasalazine
• Other aminosalicylates
• Other myelosuppressive medicines
• Medicines that can affect the liver

Give your healthcare professional a complete list of prescription medicines, over-the-counter products, vitamins, and supplements before treatment.

Who Should Tell Their Doctor Before Taking 6-MP?

Tell your healthcare professional if you have:

• Liver disease
• Kidney disease
• An active infection
• Low blood-cell counts
• A history of problems with mercaptopurine or thioguanine
• TPMT or NUDT15 deficiency
• Pregnancy or plans for pregnancy
• Breastfeeding plans
• A planned surgery or dental procedure

Also provide your complete medication history. This information helps your healthcare team identify interactions and determine the monitoring schedule.

What Happens If You Miss a Mercaptopurine Dose?

If you forget a dose, follow the instructions provided by your oncology team.

MedlinePlus advises taking a missed dose when remembered unless it is almost time for the next dose. In that situation, skip the missed dose and continue the regular schedule. Do not take a double dose.

Can You Stop Mercaptopurine Suddenly?

Do not stop mercaptopurine without speaking with your oncology team.

The medicine can form an important part of a planned leukemia maintenance regimen. Therefore, missed treatment or unsupervised changes can affect the overall treatment plan.

How Long Does Mercaptopurine Treatment Last?

Treatment duration varies according to the leukemia protocol and the patient’s response.

For ALL, mercaptopurine can form part of long-term maintenance chemotherapy. Your oncology team will determine the duration and make adjustments based on blood counts, liver tests, treatment response, and other factors.

6-MP 50mg Storage

• Keep the tablets in their original packaging.
• Store them according to the product label.
• Protect the medicine from excessive heat and moisture.
• Keep the tablets away from children and pets.
• Do not use damaged or improperly stored tablets.

Frequently Asked Questions About 6-MP 50mg

What is 6-MP 50mg?

6-MP 50mg contains mercaptopurine 50mg. It is an antimetabolite medicine used primarily as part of combination chemotherapy for acute lymphoblastic leukemia.

What does 6-MP stand for?

6-MP stands for 6-mercaptopurine, the active ingredient mercaptopurine.

What is mercaptopurine used for?

Current U.S. labeling indicates mercaptopurine tablets for adult and pediatric patients with acute lymphoblastic leukemia as part of combination chemotherapy maintenance. :contentReference[oaicite:18]{index=18}

What are mercaptopurine side effects?

Possible effects include nausea, vomiting, diarrhea, rash, hair loss, and skin darkening. More serious problems can include low blood counts, infection, liver injury, and immune suppression.

Is mercaptopurine chemotherapy?

Yes. Mercaptopurine is an antimetabolite chemotherapy medicine and can form part of combination chemotherapy for ALL.

What is the mercaptopurine 50mg dose?

There is no single dose that fits every patient. Current U.S. labeling gives a weight-based starting range of 1.5mg/kg to 2.5mg/kg once daily for ALL maintenance, with dose adjustments based on blood counts and other factors.

Can mercaptopurine be taken with allopurinol?

The medicines can interact significantly. If they must be used together, the mercaptopurine dose requires adjustment and medical monitoring.

Is mercaptopurine the same as 6-MP?

Yes. 6-MP is the common abbreviation for 6-mercaptopurine, the active ingredient in 6-MP 50mg tablets.

Is 6-MP 50mg FDA approved?

Mercaptopurine tablets are an FDA-approved medicine in the United States, with an initial U.S. approval dating to 1953. Current U.S. labeling indicates use for ALL as part of combination chemotherapy maintenance. This does not establish FDA approval for the specific international 6-MP/Zydus product or packaging shown on this page.

U.S. Medical Information and References

For reliable medical information, consult authoritative U.S. sources:

• DailyMed – Mercaptopurine Tablets
  
• MedlinePlus – Mercaptopurine
  
• FDA – Mercaptopurine 50mg Label
  
• FDA – Drugs Information
  

Explore More Medicines

Visit our online medicine shop to explore available products and medicine categories.

You can also return to our home page for additional medicine information.

Important Regulatory Information

6-MP 50mg shown on this page is an international branded product containing mercaptopurine 50mg. Product registration, labeling, dispensing requirements, and import rules can differ between countries.

U.S. sources cited above describe FDA-approved mercaptopurine products and current U.S. labeling. These references do not establish FDA approval for the specific Zydus/Cadila 6-MP packaging shown on this page.

U.S. patients and healthcare professionals should verify the regulatory status, prescription requirements, labeling, and legal availability of the exact product before use or dispensing.

Medical Disclaimer

This page provides general educational information only. It does not replace advice from an oncologist, doctor, pharmacist, or other qualified healthcare professional.

Mercaptopurine is a potent prescription chemotherapy medicine. It can cause serious blood, liver, immune, and other adverse effects. Do not start, stop, or change treatment based only on information on this website.

Always discuss your diagnosis, laboratory results, current medicines, genetic risk factors, pregnancy status, and complete treatment plan with your healthcare professional.